Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$689M |
| 2 |
Broadcom
AVGO
|
+$153M |
| 3 |
Walmart Inc
WMT
|
+$136M |
| 4 |
Amazon
AMZN
|
+$104M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$102M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$71.5M |
| 2 |
Pinnacle West Capital
PNW
|
+$49.1M |
| 3 |
Procter & Gamble
PG
|
+$43.7M |
| 4 |
Chevron
CVX
|
+$43.1M |
| 5 |
Hershey
HSY
|
+$43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.62% |
| 2 | Healthcare | 9.42% |
| 3 | Industrials | 7.55% |
| 4 | Financials | 6.82% |
| 5 | Consumer Discretionary | 6.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Criteo S.A.
CRTO
$854M
| $215K | ﹤0.01% |
+10,418
| New | +$216K |
|
1377
Dakota Gold
DC
$822M
| $214K | ﹤0.01% |
37,626
-74,445
| -66% | -$358K |
|
1378
Oxford Industries
OXM
$556M
| $213K | ﹤0.01% |
6,241
-12,473
| -67% | -$464K |
|
1379
CAMP4 Therapeutics
CAMP
$281M
| $213K | ﹤0.01% |
+34,720
| New | +$148K |
|
1380
Mayville Engineering Co
MEC
$544M
| $212K | ﹤0.01% |
11,316
-14,723
| -57% | -$240K |
|
1381
Vale
VALE
$64.4B
| $211K | ﹤0.01% |
+16,174
| New | +$196K |
|
1382
Amprius Technologies
AMPX
$1.45B
| $210K | ﹤0.01% |
+26,560
| New | +$304K |
|
1383
Riley Exploration Permian
REPX
$833M
| $209K | ﹤0.01% |
+7,905
| New | +$210K |
|
1384
CALL
Huntington Ingalls Industries
HII
$11.6B
| $204K | ﹤0.01% |
600
-700
| -54% | -$217K |
|
1385
Ranpak Holdings
PACK
$436M
| $204K | ﹤0.01% |
+37,642
| New | +$198K |
|
1386
FB Financial Corp
FBK
$2.93B
| $203K | ﹤0.01% |
+3,637
| New | +$203K |
|
1387
ADC Therapeutics
ADCT
$124M
| $200K | ﹤0.01% |
56,783
+10,842
| +24% | +$44K |
|
1388
Neogen
NEOG
$2.58B
| $199K | ﹤0.01% |
+28,516
| New | +$179K |
|
1389
NeoGenomics
NEO
$2.14B
| $197K | ﹤0.01% |
+16,718
| New | +$180K |
|
1390
Macerich
MAC
$6.89B
| $192K | ﹤0.01% |
+10,379
| New | +$183K |
|
1391
Seres Therapeutics
MCRB
$46.2M
| $190K | ﹤0.01% |
+12,737
| New | +$222K |
|
1392
Marten Transport
MRTN
$1.2B
| $189K | ﹤0.01% |
16,593
-24,774
| -60% | -$263K |
|
|
FRMM
1393
Forum Markets
FRMM
$73.4M
| $186K | ﹤0.01% |
+38,048
| New | +$537K |
|
1394
Aspen Aerogels
ASPN
$418M
| $185K | ﹤0.01% |
65,470
-50,952
| -44% | -$263K |
|
1395
Global X Uranium ETF
URA
$6.45B
| $183K | ﹤0.01% |
4,291
| – | – |
|
|
FCRS.WS
1396
FutureCrest Acquisition Corp Warrants
FCRS.WS
| $183K | ﹤0.01% |
+250,000
| New | +$195K |
|
|
ELME
1397
Elme Communities
ELME
$148M
| $178K | ﹤0.01% |
+10,208
| New | +$173K |
|
1398
Lightpath Technologies
LPTH
$841M
| $177K | ﹤0.01% |
+16,356
| New | +$133K |
|
1399
Evolus
EOLS
$557M
| $174K | ﹤0.01% |
26,206
-7,864
| -23% | -$53.3K |
|
|
EU
1400
enCore Energy
EU
$243M
| $172K | ﹤0.01% |
+69,465
| New | +$199K |
|
Similar funds
Michael Gelband's Q4 2025 Portfolio in Review
As of Q4 2025, Michael Gelband held 2,189 positions worth $12.7B, up 30% from $9.79B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Michael Gelband deployed $2.85B of net new capital in Q4 2025, opening 723 new positions and adding to 409 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 15% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Procter & Gamble, an estimated $43.7M trimmed.
- Michael Gelband's largest Q4 2025 buy was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
- Michael Gelband added most to NVIDIA in Q4 2025, an estimated $689M increase.
- Michael Gelband's biggest Q4 2025 reduction was Procter & Gamble, cutting an estimated $43.7M.
- Michael Gelband fully exited Meta Platforms (Facebook) in Q4 2025, selling an estimated $71.5M.
- Michael Gelband's ten largest holdings make up 30% of its $12.7B portfolio in Q4 2025.
- Michael Gelband opened 723 new positions and closed 716 in Q4 2025.
- Michael Gelband's portfolio value rose 30% quarter-over-quarter to $12.7B.
Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.